{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:33:56Z","timestamp":1792503236431,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-2022HER2AZMS-0291"],"award-info":[{"award-number":["Y-2022HER2AZMS-0291"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172720"],"award-info":[{"award-number":["82172720"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijrobp.2025.09.042","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:25:33Z","timestamp":1759537533000},"page":"733-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Proton Therapy May Reduce the Risk of Cancer Progression During Immune Checkpoint Inhibitor Therapy: A Propensity Score-Matched Analysis of Intensity Modulated Proton Versus Photon Radiation Therapy"],"prefix":"10.1016","volume":"124","author":[{"given":"Cong","family":"Bo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.09.042_bib0001","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0003","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: A Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0005","first-page":"1","article-title":"Radio-induced lymphopenia in the era of anti-cancer immunotherapy","volume":"378","author":"de Kermenguy","year":"2023","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0006","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: A pooled analysis of trials in the US Food and Drug Administration database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0007","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0008","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in Stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0009","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jaad.2024.06.023","article-title":"Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis","volume":"91","author":"Nardone","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0010","article-title":"Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers","volume":"14","author":"Rykkelid","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0011","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0012","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: The dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2021.09.004","article-title":"Current status and application of proton therapy for esophageal cancer","volume":"164","author":"Wang","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0014","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/cac2.12576","article-title":"Beyond success: Unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors","volume":"44","author":"Wu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0015","doi-asserted-by":"crossref","first-page":"N131","DOI":"10.1088\/0031-9155\/56\/11\/N01","article-title":"Creating a spread-out Bragg peak in proton beams","volume":"56","author":"Jette","year":"2011","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0016","first-page":"1227","volume":"109","author":"Greco","year":"2007","journal-title":"Current status of radiotherapy with proton and light ion beams. Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0017","first-page":"106","article-title":"Prospect of radiotherapy technology development in the era of immunotherapy","volume":"2","author":"Jin","year":"2022","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0018","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.radonc.2017.11.028","article-title":"Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy","volume":"128","author":"Shiraishi","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0019","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2023.08.058","article-title":"Severe lymphopenia during chemoradiation therapy for esophageal cancer: Comprehensive analysis of randomized phase 2B trial of proton beam therapy versus intensity modulated radiation therapy","volume":"118","author":"Wang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2020.12.019","article-title":"Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy","volume":"156","author":"Kim","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/09553002.2024.2324472","article-title":"Kaplan lecture 2023: Lymphopenia in particle therapy","volume":"100","author":"Durante","year":"2024","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0022","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","article-title":"Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: Phase II randomized study of protons vs photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijrobp.2016.02.022","article-title":"Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing","volume":"95","author":"Gameiro","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0024","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12951-024-02855-0","article-title":"Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3","volume":"22","author":"Hu","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216268","article-title":"Particle radiotherapy in the era of radioimmunotherapy","volume":"567","author":"Zhou","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004849","article-title":"iRECIST and atypical patterns of response to immuno-oncology drugs","volume":"10","author":"Ramon-Patino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2023.103169","article-title":"NTCP modelling of xerostomia after radiotherapy for oropharyngeal cancer using the PRO-CTCAE and CTCAE scoring systems at different time-points post-RT","volume":"116","author":"Tzikas","year":"2023","journal-title":"Phys Med"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0029","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1200\/JCO.2020.38.15_suppl.9045","article-title":"AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC)","volume":"38","author":"Ross","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0030","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12885-020-06716-5","article-title":"TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma","volume":"20","author":"Bando","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0031","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.4143\/crt.2023.502","article-title":"Phase II trial of combined durvalumab plus tremelimumab with proton therapy for recurrent or metastatic head and neck squamous cell carcinoma","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0032","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00262-022-03360-9","article-title":"Determinants of activity and efficacy of anti-PD1\/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: A longitudinal prospective biomarker-based study","volume":"72","author":"Garc\u00eda-Corbacho","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0033","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-21-2335","article-title":"A pan-cancer immunogenomic atlas for immune checkpoint blockade immunotherapy","volume":"82","author":"Yang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0034","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007440","article-title":"Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden","volume":"11","author":"Florou","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0036","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0037","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0038","doi-asserted-by":"crossref","first-page":"199","DOI":"10.21037\/tlcr.2018.04.12","article-title":"Proton therapy for early-stage non-small cell lung cancer (NSCLC)","volume":"7","author":"Gomez","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0039","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.cllc.2022.07.017","article-title":"Cardiopulmonary toxicity following intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for stage III non-small cell lung cancer","volume":"23","author":"Yu","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0040","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jtho.2023.12.021","article-title":"Comparative effectiveness of intensity-modulated proton therapy versus intensity-modulated radiotherapy for patients with inoperable esophageal squamous cell carcinoma undergoing curative-intent concurrent chemoradiotherapy","volume":"19","author":"Chang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0041","article-title":"Multi-institutional comparison of intensity modulated photon versus proton radiation therapy in the management of squamous cell carcinoma of the anus","volume":"6","author":"Mohiuddin","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0042","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbrc.2021.11.004","article-title":"Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams","volume":"585","author":"Du","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijrobp.2025.09.042_bib0043","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1080\/0284186X.2023.2238550","article-title":"Using immunotherapy to enhance the response of a C3H mammary carcinoma to proton radiation","volume":"62","author":"Nielsen","year":"2023","journal-title":"Acta Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625063060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625063060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:15:28Z","timestamp":1773310528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625063060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0360301625063060"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.042","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Therapy May Reduce the Risk of Cancer Progression During Immune Checkpoint Inhibitor Therapy: A Propensity Score-Matched Analysis of Intensity Modulated Proton Versus Photon Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}